GGrantIndex
← Leaderboards

Tal Kafri

University Of North Carolina Chapel Hill

$11,523,888
Attributed
$11,523,888
Total exposure
5
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.1M · FY200523
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$11,523,888 · 5

By mechanism

R01$11,052,950 · 3
R21$396,208 · 1
R56$74,730 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of North Carolina Chapel Hill

Same institution · by research overlap

Others in their field

Top investigators on “Gene Therapy

Research focus

Gene TherapyMediatingVectorGene DeliveryViral VectorIn VivoLentivirus VectorHepaticMouse ModelProductionCellsMutantGene Delivery SystemExhibitsFactor IxBaseImmune ResponseTransduction EfficiencyGene ExpressionIn VitroLaboratoriesLiverProtocols DocumentationTransgene Expression

Grant awards (29)

The circadian rhythm as a lentiviral vector restriction factor$722,551
R01 · FY2023 · HL · contact PI
The circadian rhythm as a lentiviral vector restriction factor$739,656
R01 · FY2022 · HL · contact PI
The circadian rhythm as a lentiviral vector restriction factor$755,206
R01 · FY2021 · HL · contact PI
The circadian rhythm as a lentiviral vector restriction factor$770,756
R01 · FY2020 · HL · contact PI
Nonintegrating Lentiviral Vectors Towards Clinical Trials$380,000
R01 · FY2019 · DK · contact PI
Lentiviral Vector-Based Gene Therapy and The Host Genetic Background$758,060
R01 · FY2018 · HL · contact PI
Nonintegrating Lentiviral Vectors Towards Clinical Trials$380,000
R01 · FY2018 · DK · contact PI
Lentiviral Vector-Based Gene Therapy and The Host Genetic Background$758,060
R01 · FY2017 · HL · contact PI
Nonintegrating Lentiviral Vectors Towards Clinical Trials$380,000
R01 · FY2017 · DK · contact PI
Lentiviral Vector-Based Gene Therapy and The Host Genetic Background$758,060
R01 · FY2016 · HL · contact PI
Nonintegrating Lentiviral Vectors Towards Clinical Trials$380,000
R01 · FY2016 · DK · contact PI
Lentiviral Vector-Based Gene Therapy and The Host Genetic Background$758,060
R01 · FY2015 · HL · contact PI
Nonintegrating Lentiviral Vectors Towards Clinical Trials$319,242
R01 · FY2014 · DK · contact PI
Nonintegrating Lentiviral Vectors Towards Clinical Trials$308,069
R01 · FY2013 · DK · contact PI
Nonintegrating Lentiviral Vectors Towards Clinical Trials$319,242
R01 · FY2012 · DK · contact PI
Nonintegrating Lentiviral Vectors Towards Clinical Trials$366,945
R01 · FY2011 · DK · contact PI
Episomal lenti vector for a humanized hemophilia mouse$260,319
R01 · FY2010 · DK · contact PI
Episomal lenti vector for a humanized hemophilia mouse$53,636
R01 · FY2010 · DK · contact PI
Episomal lenti vector for a humanized hemophilia mouse$262,949
R01 · FY2009 · DK · contact PI
Episomal lenti vector for a humanized hemophilia mouse$262,949
R01 · FY2008 · DK · contact PI
Episomal lenti vector for a humanized hemophilia mouse$268,315
R01 · FY2007 · DK · contact PI
Novel Viral Vector Delivery for Efficient ShRNA Expression$177,208
R21 · FY2007 · HL · contact PI
Novel Viral Vector Delivery Efficient ShRNA Expression$219,000
R21 · FY2006 · HL · contact PI
Episomal lenti vector for a humanized hemophilia mouse$74,730
R56 · FY2006 · DK · contact PI
LENTIVIRAL VECTOR BASED GENE THERAPY FOR LIVER DISEASES$218,250
R01 · FY2005 · DK
LENTIVIRAL VECTOR BASED GENE THERAPY FOR LIVER DISEASES$218,250
R01 · FY2004 · DK
LENTIVIRAL VECTOR BASED GENE THERAPY FOR LIVER DISEASES$218,250
R01 · FY2003 · DK
LENTIVIRAL VECTOR BASED GENE THERAPY FOR LIVER DISEASES$218,250
R01 · FY2002 · DK
LENTIVIRAL VECTOR BASED GENE THERAPY FOR LIVER DISEASES$217,875
R01 · FY2001 · DK